Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Neoplasm Metastasis 7Lung Neoplasms 5Neoplasms 3Adenocarcinoma 3Recurrence 2Lymphoma, Large-Cell, Anaplastic 2Granuloma, Plasma Cell 2Colorectal Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Relapsed Pediatric Solid Tumor 1Rare Tumor 1Neurofibromatosis 2 1Lymphoma, Follicular 1Lung Adenocarcinoma Metastatic 1Glioma 1Glioblastoma 1Gallbladder Neoplasms 1Endometrial Cancer Recurrent 1Diffuse Intrinsic Pontine Glioma 1Castration-resistant Prostate Cancer 1Carcinoma, Squamous Cell 1Carcinoma, Lobular 1Breast Neoplasms 1Advanced Cancers 1

Interventions

enzalutamide 4abiraterone 2Radiotherapy 2Metastasectomy 2Abiraterone Acetate 2testosterone enanthate 1pembrolizumab 1Radium-223 1Radiosurgery 1Prednisone 1Ketoconazole 1Injections 1Hydrocortisone 1Flutamide 1Crizotinib 1Control Groups 1Carboplatin 1Calcitriol 1Blood Specimen Collection 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Castration-resistant Prostate Cancer × Crizotinib × Clear all
NCT02207504 2022-01-06

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 1 Completed
24 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡